FDA PCAC Vote Results: 6 of 7 Peptides Recommended — Full Breakdown

The most consequential regulatory event for peptides in three years is over. On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met at the agency's White Oak campus and voted on whether seven peptides should be recommended for the Section 503A Bulk Drug Substances List — the list that determines what licensed compounding pharmacies may legally prepare with a prescription.

The committee recommended six of the seven. Only one — emideltide, better known as DSIP — was rejected. Here is the complete scorecard.

The Complete Vote Results

*Day 2 tallies as reported from the live webcast; the official FDA transcript is pending. Free base and acetate forms were voted on separately for each compound, with matching results.

Why These Votes Are Remarkable

FDA career scientists recommended against adding all seven substances in the agency's own briefing documents. The committee overrode its own staff on six of them — something advisory committees rarely do even once, let alone six times in two days. Every vote was close. A 14-member panel splitting 8–6 repeatedly against the agency's written position tells you the evidence base is genuinely contested, not settled in either direction.

FDA staff's core objections were consistent across all seven compounds: available human studies are small and short, and — more fundamentally — there are no universally accepted chemical definitions for these substances. Staff noted the agency has encountered multiple different active molecules all being marketed as "BPC-157." Without standardized identity, they argued, basic quality and comparability cannot be assessed.

The panel's majority countered with a harm-reduction argument: since the 2023 restrictions, demand has not disappeared — it has shifted to gray-market research vendors and overseas suppliers with no pharmacist, no prescriber, and no oversight. Bringing these compounds into licensed 503A compounding, they argued, is safer than the status quo.

What the Votes Do Not Mean

There is also a sobering precedent. Glutathione cleared this same committee in June 2022 by a similar margin — and it still has not been added to the codified list four years later. A favorable PCAC vote has historically been necessary but never sufficient on any predictable schedule. The codified 503A bulks list currently contains just six substances, five of them limited to topical use. Adding six peptides would more than double it, which is exactly why the FDA is likely to move deliberately.

The Politics Around the Panel

This meeting did not happen in a vacuum. HHS Secretary Robert F. Kennedy Jr. has publicly promoted peptides, and the reconstituted PCAC roster drew scrutiny before the meeting for including more members who prescribe, produce, or advise companies in the peptide space than previous panels, which were composed mainly of academics. Several dissenting members warned that the public would read a favorable vote as an efficacy endorsement — which it is not. Both the enthusiasm and the criticism are part of the story, and both will shape how the FDA handles the rulemaking phase.

What Happens Next

• FDA review: The agency evaluates the committee's recommendations, the meeting record, and public comments. No deadline applies.
• Possible rulemaking: If the FDA proceeds, a proposed rule is published, a comment period follows, and a final rule codifies any additions. Historically this takes 12–24 months when it happens at all.
• Next PCAC round: The FDA has signaled another PCAC consultation involving GHK-Cu for noninjectable routes before the end of February 2027.

Until a final rule exists, the legal landscape is exactly what it was on July 22: these peptides remain unavailable through compounding pharmacies, and the only markets are research-grade supply and, for a small subset of related compounds, licensed prescription products. For a provider-side view of what this means for telehealth access, see the coverage at Veritide's regulation tracker.